



REVIEW

Open Access

Malignant peripheral nerve sheath tumours in inherited disease

D Gareth R Evans^{1,3*}, Susan M Huson¹ and Jillian M Birch²

Abstract

Background: Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes.

Methods: The North West Regional Genetic Register covers a population of 4.1 million and was interrogated for incidence of MPNST in 12 cancer prone syndromes. Age, incidence and survival curves were generated for NF1.

Results: Fifty two of 1254 NF1 patients developed MPNST, with MPNST also occurring in 2/181 cases of schwannomatosis and 2/895 NF2 patients. Three cases were also noted in *TP53* mutation carriers. However, there were no cases amongst 5727*BRCA1/2* carriers and first degree relatives, 2029 members from Lynch syndrome families, nor amongst 447 Familial Adenomatous Polyposis, 202 Gorlin syndrome, nor 87 vHL cases.

Conclusion: MPNST is associated with schwannomatosis and *TP53* mutations and is confirmed at high frequency in NF1. It appears to be only increased in NF2 amongst those that have been irradiated. The lifetime risk of MPNST in NF1 is between 9–13%.

Keywords: Sarcoma, MPNST, NF1, Li Fraumeni, *TP53*, *SMARCB1*, NF2

Introduction

Malignant peripheral nerve sheath tumour (MPNST) are uncommon tumours varying substantially in clinicopathologic features [1]. Previous studies have shown that 20%–50% of patients with MPNST also have Neurofibromatosis type 1 (NF1) [2-4]. Cutaneous MPNST is very rare [5-7]; skin involvement is usually secondary to local invasion or metastasis from larger underlying tumours. Most are high grade, poorly differentiated and aneuploid. Only half can be shown to exhibit schwannian differentiation by immunohistochemical methods. Tumours exhibiting mesenchymal primarily rhabdomyosarcomatous differentiation (Triton tumour) are often associated with NF1 [8]. The lifetime risk of MPNST in NF1 has previously been assessed as between 8–13% [4]. However, there has been limited evidence of association with other tumour prone disorders, with only case

reports showing associations with *TP53* mutations [9] and schwannomatosis[10]. We have reviewed our genetic register databases for presence of MPNST amongst affected cases and for non-syndromic conditions their first degree relatives (FDRs). The conditions studied are summarised in Table 1.

Methods

The North West Regional Genetic Register covers a region of North West England, based around Manchester, with a population of 4.1 million. The genetic register service covers a number of tumour predisposing syndromes in particular NF1, Neurofibromatosis type 2 (NF2), Familial Adenomatous Polyposis (FAP), Gorlin syndrome, von Hippel Lindau disease and non-syndromic families with *BRCA1*, *BRCA2*, *MSH2*, *MLH1* and *MSH6* mutations. The register is highly ascertained for NF1, NF2, FAP, Gorlin syndrome von Hippel Lindau disease [11]. In addition there is a regional database of *TP53* mutation carriers and an international database for schwannomatosis patients referred into the Manchester laboratory for *SMARCB1* mutation analysis. All the registries have been the subject of cancer verification using the regional

* Correspondence: gareth.evans@cmft.nhs.uk

¹Genetic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, St. Mary's Hospital, Oxford Road, Manchester M13 9WL, UK

³Manchester Academic Health Science Centre, Genetic Medicine, St Mary's Hospital, Central Manchester Hospitals Foundation Trust, Manchester M13 9WL, UK

Full list of author information is available at the end of the article

Table 1 Diagnostic criteria for NF1 (two or more must be present)

Disease	Birth incidence	Main tumour associations	Known risk of MPNST
NF1	1 in 2,712	Neurofibroma, MPNST, gliomaAML, phaeochromocytoma	yes
Schwannomatosis	1 in 100,000	Schwannoma, meningioma	No
NF2	1 in 33,000	Schwannoma, meningioma, ependymoma	Only after irradiation
BRCA1	1 in 900	Breast cancer, Ovarian cancer	No
BRCA2	1 in 850	Breast cancer, Ovarian cancer, prostate cancer	No
TP53	1 in 3000	Breast cancer, sarcoma, glioma, lung cancer, adreno-cortical	possible
FAP	1 in 8,619	Colorectal, duodenal, hepatoblastoma, thyroid	No
MSH2	1 in 2000	Colorectal, endometrium, ovarian, upper urothelial, gastric, glioma	No
MLH1	1 in 2000	Colorectal, endometrium, ovarian, upper urothelial, gastric, glioma	No
MSH6	1 in 10,000	Colorectal, endometrium, ovarian, upper urothelial, gastric, glioma	No
vHL	1 in 42,987	Renal cancer, haemangioblastoma	No
Gorlin syndrome	1 in 18,976	Basal cell carcinoma, medulloblastoma	No

North West Cancer Intelligence Service (NWCIS). We have previously published risks of cancers in Lynch syndrome [12] and cancer incidence in *BRCA1* and *BRCA2* carriers [13]. The NWCIS ascertains patients with malignancies of all sites, as well as benign central nervous system tumours, from pathology records and death certificates. We previously reviewed the Cancer Register for patients with MPNST (ICD-0: M9540/3 and 9560/3) from 1984–1996 [4]. We reviewed hospital notes for all patients with MPNST who were identified for the study. To corroborate a diagnosis of NF1, histology reports and details of other typical NF1 disease features were reviewed (e.g., café-au-lait macules and neurofibromas with respect to the U.S. National Institutes of Health diagnostic criteria[11]). As a diagnosis is straightforward in most cases of NF1, NF2, vHL, Gorlin syndrome and FAP only affected cases were used in the analysis. As previously we also used all FDRs of known mutation carriers for Lynch syndrome (*MSH2*, *MLH1*, *MSH6*) [12] and *BRCA1/2* [14] as 50% of these are likely to carry the pathogenic mutation.

Death details from the registries were used to calculate survival rates, and death certificates were reviewed to determine cause of death. Follow-up was censored on 1st April 2010. MPNST incidence curves were derived for NF1 for strict regional residents to avoid ascertainment bias. Five-year survival was determined using Kaplan-Meier curves. NF1 MPNST cases who were identified on the periphery of the region during the study period were included for the survival analysis only. The Mann–Whitney *U* test and Wilcoxon (Gehan) statistic were used to test between-group differences in age at diagnosis and survival.

Results

The presence of MPNST among the study populations is shown in Table 2. There were no instances of MPNST

amongst 5727 *BRCA1/2* carriers and first degree relatives, nor among 2029 Mismatch Repair mutation carriers and first degree relatives from Lynch syndrome families. As the annual rate of MPNST is about 1.25 per million [4] the lifetime risk in the general population would be about 1 in 10,000. There could be some confidence therefore that MPNST does not occur at increased incidence in *BRCA1/2* carriers but not yet in Lynch syndrome. There were also no cases amongst vHL, Gorlin or FAP patients although numbers were smaller. The presence of two male cases with MPNST aged 32 (retro-orbital) and 33 years (lower limb) and one female case of triton tumour aged 5 years amongst carriers of a 524 G>A (Arg175His), a 574delC and a 375 G>A *TP53* mutation respectively suggests a likely association with Li Fraumeni syndrome. The 375 G>A mutation affects the invariant splice donor site CG/g>CA/g in exon 4. The missense and splicing mutation were inherited, but the frameshift deletion *de novo*. There were also a further three benign nerve sheath tumours in three further unrelated *TP53* mutation carriers aged 33 years (Vestibular schwannoma) and two paraspinal/extra-dural at ages 50 and 49 years. There were also three cases with schwannomatosis and MPNST. Two of these occurred in a family with a c.846 C>G, p.N288K *SMARCB1* mutation that we have previously reported as probably pathogenic [15]. It appears this Australian family has been reported as part of a hospital series, but they were not noted to have a *SMARCB1* mutation [10]. Both had high grade MPNSTs with one now metastatic aged 27 years and the other having died aged 17 years. A third case in an individual with multiple spinal (5) schwannomas and a peripheral schwannoma occurred aged 46 from which he died. *SMARCB1* mutation analysis was not possible. There were two cases occurring amongst 921 NF2 patients. Both of these have been reported as having occurred after radiation treatment

Table 2 Incidence of MPNST in 12 tumour prone genetic conditions

Disease	Cases at risk	MPNST	MPNST after radiation treatment	Sex ratioM:F	Median (range) age at diagnosis
NF1	1252	52	4	22:30	31(13.3–77.2)
Schwannomatosis	181	3	0	2:1	26(17–45)
NF2	920	2	2	1:1	25–34
BRCA1	2992*	0	0		
BRCA2	2735*	0	0		
TP53	221*	3	0	2:1	32 (1–33)
FAP	477	0	0		
MSH2	1054*	0	0		
MLH1	897*	0	0		
MSH6	178*	0	0		
vHL	87	0	0		
Gorlin syndrome	202	0	0		

*Cases include first degree relatives of known mutation carriers.

for vestibular schwannoma [16,17]. No MPNSTs occurred in unirradiated NF2 patients.

There were 52 cases of MPNST amongst our NF1 patients including 43/1059 patients within the strict regional boundaries of the Cancer Register. Fifteen cases of MPNST have occurred in the strict regional population since 1996 maintaining an incidence rate of above 1 per 1000 NF1 patient per year as 1010 NF1 patients were alive at some point after 1996.

NF1 MPNST lifetime risk

Within the strict regional population of 1059 individuals the cumulative risk of MPNST was 11.7% (95% CI 9.7–13.7%) by age 70 years (figure 1). The robustness of incidence beyond 70 years is influenced by a single case in a

female aged 77 years in a population with only 34 patients living beyond 70 years.

Discussion

The association between MPNST and NF1 has long been documented [2-4,18-22]. The present report doubles the size of our previous report of MPNST in NF1 [4] and provides further confirmation for the lifetime risk estimates. As only cases with MPNST within the strict highly ascertained borders of the region are included these remain robust. There have been fifteen MPNSTs in our regional population in the fourteen years since our last population based study [4]. The annual incidence of above 1 per 1000 NF1 patients has been maintained over now a 27-year period. The lifetime risk of MPNST in NF1 is estimated at 11.7% with tighter confidence intervals than previously. Survival remains poor in NF1 with only one third of patients alive at 5 years post diagnosis. This is in accordance with our previous publication [4]. Although we have also recently reported an improved survival in recent years (since 1996) and significantly better survival in females versus males (5-year survival 46% vs 22%) with NF1 [23]. MPNST remains the single biggest contributing factor to reduced life expectancy in NF1 [16,18,24].

In addition to the known link with NF1 this study has confirmed probable links with schwannomatosis and germline *TP53* mutations. The presence of three proven MPNSTs in only 181 schwannomatosis patients is very suggestive of an association. The main difficulty with this association is the previous problems with classifying schwannomatosis [25-27]. However, the presence of two MPNSTs in a family with a proven *SMARCB1* mutation suggests that this is a real link. It also broadens the tumour spectrum in families with *SMARCB1* mutations. There remains a question as to why children with certain *SMARCB1* mutations have a very high risk of the




Figure 1 Cumulative incidence of MPNST in NF1 patients within the strict North West region boundaries.

highly Malignant atypical teratoid Rhabdoid tumours [28] whereas other families appear to get only schwannomas [15] although meningiomas also occur at a variable frequency [15,29,30].

The presence of three confirmed *TP53* mutation carriers with MPNST makes a link with germline *TP53* mutations and Li Fraumeni syndrome very likely. It is quite possible that cases of MPNST are buried amongst reports of soft tissue sarcoma [31]. It is therefore likely that occult/unrecognized LFS patients/families could come to light from performing *TP53* analysis on MPNST patients. Both the cases of MPNST occurred after the previous report from our group [31]. Nonetheless the only clear report of a *TP53* mutation was a case of Triton tumour in a three year old [9]. This report also suggests that this was the first such case in the literature whereas the further triton tumour case in our series was evident from our previous report [31].

The link between NF2 and MPNST is controversial [16,17,32-35]. There have been a number of reports of MPNST following radiation therapy [16,17,33] in NF2, but only two reports of apparently spontaneous MPNST without radiotherapy [34,36]. The first report is, nonetheless, questionable as it describes multifocal MPNST in addition to neurofibromata, which would be more consistent with NF1 than NF2. The second describes a patient with a unilateral vestibular schwannoma that developed contralateral cranial MPNST[36] as such neither report refers to a patient with proven NF2. The first report[34] also describes the possibility of a constitutional *TP53* mutation, which in addition to an NF1 mutation may cause a very substantial risk of MPNST. Indeed *TP53* mutations have been described in the transformation from benign schwannoma to MPNST [32]. Although the risk of MPNST appears to be higher in *TP53* mutation carriers this will need to be confirmed in larger studies.

Up to 50% of malignant peripheral nerve sheath tumours in non NF1 patients harbour NF1 mutations [37]. There is a broad spectrum of NF1 mutations in MPNST and in the germline of those NF1 patients that develop MPNST [38,39]. Although the risk of MPNST appears to be substantially higher in individuals with large deletions removing the NF1 gene [40], these patients still only make up a small proportion of all cases of MPNST in NF1 [38,39]. A better test needs to be derived to target a high risk population in NF1 for screening. It is possible that assessing whole body tumour burden and particularly the extent of large deep seated tumours at age 15–20 years may detect a sub-population at enhanced risk [41]. Whilst MRI can detect volumetric changes that may presage malignant change, Positron Emission Tomography (PET) is the most sensitive and specific test to determine if a tumour has become malignant [42,43].

Nonetheless the significant dose of radiation involved in PET means this should not be used in routine screening in a cancer prone syndrome [16]. Detection of a subset at risk by genetic analysis and whole body MRI followed by regular MRI of suspicious lesions for increased volumetric growth alongside greater patient awareness may improve survival from the current poor levels in NF1.

The poor survival from MPNST particularly in NF1 patients highlights the need for therapies targeted at the main underlying genetic abnormality. Whole genome sequencing is likely to reveal new targets for therapy and the fast reducing cost of such testing may mean that it will be affordable in the clinic within the next 5 years.

In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline *TP53* mutations as well as those with NF1. Radiation treatment particularly in childhood increases the risk of MPNST in NF1 and may also cause MPNST to occur in NF2.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

The research and reviews conceived by DGE, initial manuscript and data assessed by DGE, contributions for data on TP53 from JMB and from SMH for NF1. All authors developed the manuscript and approved the final version.

Acknowledgements

We acknowledge the National Specialist Commissioning team for their support of the National Complex NF1 service and the NF2 service. The department of Genetic Medicine in Manchester is supported by the NIHR Manchester Biomedical Research Centre.

Author details

¹Genetic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, St. Mary's Hospital, Oxford Road, Manchester M13 9WL, UK. ²Cancer Research UK Paediatric and Familial Cancer Research Group, University of Manchester, Room 1.900 Stopford Building, Oxford Road, Manchester M13 9PT, UK. ³Manchester Academic Health Science Centre, Genetic Medicine, St Mary's Hospital, Central Manchester Hospitals Foundation Trust, Manchester M13 9WL, UK.

Received: 4 November 2011 Accepted: 14 March 2012

Published: 4 October 2012

References

1. Scheithauer BW, Woodruff JM, Erlandson RA: Primary malignant tumors of peripheral nerve. In *Tumors of the Peripheral Nervous System. Atlas of Tumor Pathol; Armed Forces Institute of Pathology* 1999; pp.303-72.
2. Sorensen SA, Mulvihill JJ, Nielsen A: Long term follow up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. *N Engl J Med* 1986, **314**:1010-1015.
3. D'Agostino AN, Soule EH, Miller RH: Primary malignant neoplasms of nerves (malignant neurolemmomas) in patients without multiple neurofibromatosis (Von Recklinghausen disease). *Cancer* 1963, **16**:1003-1014.
4. Evans DGR, Baser ME, McGaughran J, Sharif S, Donnelly B, Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002, **39**:311-314.
5. George E, Swanson PE, Wick MR: Malignant peripheral nerve sheath tumors of the skin. *Am J Dermatopathol* 1989, **11**:213-221.
6. Misago N, Ishii Y, Kohda H: Malignant peripheral nerve sheath tumor of the skin: a superficial form of this tumor. *J Cutan Pathol* 1996, **23**:182-188.

7. Hirose T, Scheithauer BW, Sano T: **Malignant perineurioma. A study of 7 cases.** *Am J Surg Pathol* 1998, **22**:1368–1378.
8. Woodruff JM, Perino G: **Non-germ cell or teratomatous malignant tumors showing additional rhabdomyoblastic differentiation, with emphasis on the malignant "Triton" tumor.** *Demin Diagn Surg Pathol* 1994, **11**:69–81.
9. Chao MM, Levine JE, Ruiz RE, Kohlmann WK, Bower MA, Petty EM, Mody RJ: **Malignant triton tumor in a patient with Li-Fraumeni syndrome and a novel TP53 mutation.** *Pediatr Blood Cancer* 2007, **49**(7):1000–1004.
10. Gonzalvo A, Fowler A, Cook RJ, Little NS, Wheeler H, McDonald KL, Biggs MT: **Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up.** *J Neurosurg* 2011, **114**(3):756–762.
11. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F: **Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service.** *Am J Med Genet* 2010, **152A**(2):327–332.
12. Barrow E, Robinson L, Aldhujaj W, Shenton S, Lalloo F, Hill J, Evans DG: **Extracolonic cancers in HNPCC: Cumulative lifetime incidence and tumour distribution. A report of 121 families.** *Clin Genet* 2009, **75**(2):141–149.
13. Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG: **Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.** *Fam Cancer*. 2011 Dec 21. [Epub ahead of print]
14. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER: **Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting.** *BMC Cancer* 2008, **8**(1):155.
15. Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DGR: **Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.** *J Med Genet* 2008, **45**(6):332–339.
16. Evans DGR, Birch JM, Ramsden RT, Moffat D, Baser ME: **Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes.** *J Med Genet* 2006, **43**(4):289–294.
17. Bari ME, Forster DM, Kemeny AA, Walton L, Hardy D, Anderson JR: **Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature.** *Br J Neurosurg* 2002, **16**:284–289.
18. Poyhonen M, Niemela S, Herva R: **Risk of malignancy and death due to neurofibromatosis.** *Arch Pathol Lab* 1997, **121**:139–143.
19. Rasmussen SA, Yang Q, Friedman JM: **Mortality in neurofibromatosis 1: an analysis using US death certificates.** *Am J Hum Genet* 2001, **68**:1110–1118.
20. Ducatman B, Scheithauer B, Piepgras D, Reiman H, Istrup D: **Malignant peripheral nerve sheath tumors: a clinicopathological study of 120 patients.** *Cancer* 1986, **57**:2006–2021.
21. Wanebo J, Malik J, VandenBerg S, Wanebo H, Driessen N, Persing J: **Malignant peripheral nerve sheath tumors: a clinicopathological study of 28 cases.** *Cancer* 1993, **71**:1247–1253.
22. Doorn P, Molenaar W, Buter J, Hockstra H: **Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis.** *Eur J Surg Oncol* 1995, **21**:78–82.
23. Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DG: **Malignant peripheral nerve sheath tumours in NF1: Improved survival in women and in recent years.** *Eur J Cancer* 2011, **47**(18):2723–2728.
24. Evans DG, Howard E, Moran A, Ingham S, Scott-Kitching V, Holt F, Huson SM: **Mortality in neurofibromatosis 1.** *Eur J Hum Genetics* 2011; in press.
25. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A: **Roach ES Diagnostic criteria for schwannomatosis.** *Neurology* 2005, **64**(11):1838–1845.
26. Murray A, Hughes TAT, Neal JW, Howard E, Evans DGR, Harper PS: **A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2?** *J Neurol Neurosurg Psychiatr* 2006, **77**(2):269–271.
27. Baser ME, Friedman JM, Evans DG: **Increasing the specificity of diagnostic criteria for schwannomatosis.** *Neurology* 2006, **66**(5):730–732.
28. Bourdeaut F, Lequin D, Brugières L, Reynaud S, Dufour C, Doz F, André N, Stephan JL, Pérel Y, Oberlin O, Orbach D, Bergeron C, Rialland X, Fréneaux P, Ranchere D, Figarella-Branger D, Audry G, Puget S, Evans DG, Pinas JC, Capra V, Mosseri V, Coupier I, Gauthier-Villars M, Pierron G, Delattre O: **Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor.** *Clin Cancer Res* 2011, **17**(1):31–38.
29. Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfrio B, Vivarelli R, Genuardi M, Papi L: **Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.** *Neurogenetics* 2010, **11**(1):73–80.
30. Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, Kidd AM, Hulsebos TJ: **Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.** *J Med Genet*. 2010 Oct 7. [Epub ahead of print] Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG. SMARCB1 mutations are not a common cause of multiple meningiomas. *J Med Genet*. 2010;47(8):567–8.
31. Birch JM, Alston AD, McNally RJQ, Evans DGR, Kelsey AM, Harris M, Eden OB, Varley JM: **Relative frequency and morphology of cancers in 28 Li-Fraumeni families with germline TP53 mutations.** *Oncogene* 2001, **20**:4621–4628.
32. Shin M, Ueki K, Kurita H, Kirino T: **Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery.** *Lancet* 2002, **360**:309–310.
33. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: **Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: Case report and review of the literature.** *Neuro Oncol* 2007, **9**(4):447–453.
34. Higami Y, Shimokawa I, Kishikawa M, Okimoto T, Ohtani H, Tomita M, Tsujino A, Ikeda T: **Malignant peripheral nerve sheath tumors developing multifocally in the central nervous system in a patient with neurofibromatosis type 2.** *Clin Neuropathol* 1998, **17**(2):115–120.
35. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, Gokden M, Spinner RJ: **Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases.** *Am J Surg Pathol* 2009, **33**(3):325–338.
36. Ziadi A, Saliba I: **Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.** *Auris Nasus Larynx* 2010, **37**(5):539–545.
37. Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, Lothe RA, Dallapiccola B: **Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.** *J Pathol* 2009, **217**(5):693–701.
38. Upadhyaya M, Kluwe L, Spurlock G, Mantripragada K, Monem B, Majounie E, Chuzanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V: **The germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumours (MPNSTs).** *Hum Mutation* 2008, **29**(1):74–82.
39. Upadhyaya M, Spurlock G, Majounie E, Griffiths S, Forrester N, Baser M, Huson SM, Gareth Evans D, Ferner R: **The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral nerve sheath tumours (MPNSTs).** *Hum Mutat* 2006, **27**(7):716.
40. De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciort R, Legius E: **Elevated risk for MPNST in NF1 microdeletion patients.** *Am J Hum Genet* 2003 May, **72**(5):1288–1292.
41. Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM: **Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.** *Neuro Oncol* 2008, **10**(4):593–598.
42. Ferner RE, Lucas JD, O'Doherty MJ, et al: **Evaluation of (18) fluorodeoxyglucose positron emission tomography (FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform tumours in neurofibromatosis 1.** *J Neurol Neurosurg Psychiatr* 2000, **68**:353–357.
43. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M: **[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.** *Ann Oncol* 2008, **19**(2):390–394.

doi:10.1186/2045-3329-2-17

Cite this article as: Evans et al: Malignant peripheral nerve sheath tumours in inherited disease. *Clinical Sarcoma Research* 2012 **2**:17.